Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2025 First-in-Human Study in Healthy Subjects
NCT05726851Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2025 in Alzheimer's disease (AD) (7 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Abnormal Laboratory Values and 4 more. Started Feb 2023; status: completed.
02
Drugs
E2025
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05726851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726851.